VX-702
VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β[1].
Product Specifications
CAS Number
745833-23-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; p38 MAPK
Type
Reference compound
Related Pathways
Autophagy; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/VX-702.html
Purity
99.69
Solubility
DMSO : ≥ 42 mg/mL
Smiles
O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O
Molecular Formula
C19H12F4N4O2
Molecular Weight
404.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Kuliopulos A, et al. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost, 2004, 92 (6), 1387-1393.|[2]Braddock M, IDDB Meeting Report, 2005, March 14-15.|[3]Gill A, IDDB Meeing Report, 2002, March 06-08.|[4]Naka K, et al. Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat Commun. 2015 Aug 20;6:8039.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![tert-Butyl 4'-Iodo-1',2'-dihydrospiro[azetidine-3,3'-indole]-1-carboxylate](https://cdn.genprice.uk/products/572/12051510/imageurl/trc-b448585-25mg.webp)
TRC-B448585-25MG 25 mg
tert-Butyl 4'-Iodo-1',2'-dihydrospiro[azetidine-3,3'-indole]-1-carboxylate
Sign In for Pricing
View Details 
